Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes

Blood

Volumn 94, Issue 12, 1999, Pages 4177-4185

  Kietzmann, Thomas ^a   Roth, Ulrike ^a   Jungermann, Kurt ^a  

^a Inst fur Biochem/Molek Zellbiol   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; DACTINOMYCIN; HYPOXIA INDUCIBLE FACTOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA FLANKING REGION; GENE EXPRESSION REGULATION; HYPOXIA; LIVER CELL; MALE; NONHUMAN; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN INDUCTION; RAT;

EID: 0032795850     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.12.4177     Document Type: Article

References (63)

1. Kruithof EK, Tran TC, Bachmann F: The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemost 55:65, 1986
2. Kruithof EK, Vassalli JD, Schleuning WD, Mattaliano RJ, Bachmann F: Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 261:11207, 1986
3. Loskutoff DJ, Sawdey M, Mimuro J: Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 9:87, 1989
4. Kruithof EK, Baker MS, Bunn CL: Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86:4007, 1995
5. Bachmann F: The enigma PAI-2. Gene expression, evolutionary and functional aspects. Thromb Haemost 74:172, 1995
6. Fearns C, Loskutoff DJ: Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. Am J Pathol 150:579, 1997
7. Erickson LA, Hekman CM, Loskutoff DJ: The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA 82:8710, 1985
8. Reilly CF, McFall RC: Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 266:9419, 1991
9. Le-Magueresse BB, Pernod G, Kolodie L, Morera AM, Benahmed M: Tumor necrosis factor-alpha regulates plasminogen activator inhibitor-1 in rat testicular peritubular cells. Endocrinology 138:1097, 1997
10. Busso N, Nicodeme E, Chesne C, Guillouzo A, Belin D, Hyafil F: Urokinase and type 1 plasminogen activator inhibitor production by normal human hepatocytes: Modulation by inflammatory agents. Hepatology 20:186, 1994
11. Heaton JH, Nebes VL, O'Dell LG, Morris-SM J, Gelehrter TD: GLucocorticoid and cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor gene expression in primary cultures of rat hepatocytes. Mol Endocrinol 3:185, 1989
12. Podor TJ, Loskutoff DJ: Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor in the extracellular matrix of transforming growth factor-beta-activated endothelial cells. Ann N Y Acad Sci 667:46, 1992
13. Collen D, Lijnen HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78:3114, 1991
14. Agrenius V, Chmielewska J, Widstrom O, Blomback M: Pleural fibrinolytic activity is decreased in inflammation as demonstrated in quinacrine pleurodesis treatment of malignant pleural effusion. Am Rev Respir Dis 140:1381, 1989
15. Eddy AA, Giachelli CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 47:1546, 1995
16. Dieval J, Nguyen G, Gross S, Delobel J, Kruithof EK: A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 77:528, 1991
17. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D: Brief report: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 327:1729, 1992
18. Lee MH, Vosburgh E, Anderson K, McDonagh J: Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 81:2357, 1993
19. Quax PH, van-den HC, Verheijen JH, Padro T, Zeheb R, Gelehrter TD, van BT, Kuiper J, Emeis JJ: Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 265:15560, 1990
20. Hamsten A, de FU, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3, 1987
21. Nilsson IM, Ljungner H, Tengborn L: Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J Clin Res Ed 290:1453, 1985
22. Vaughan DE, Declerck PJ, Van HE, De MM, Collen D: Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost 68:60, 1992
23. CoLucci M, Paramo JA, Collen D: Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75:818, 1985
24. Yamashita M, Darlington DN, Weeks EJ, Jones RO, Gann DS: Plasminogen activator inhibitor-1 rises after hemorrhage in rats. Am J Physiol 268:E1065, 1995
25. Nauck M, Wolfle D, Katz N, Jungermann K: Modulation of the glucagon-dependent induction of phosphoenolpyruvate carboxykinase and tyrosine aminotransferase by arterial and venous oxygen concentrations in hepatocyte cultures. Eur J Biochem 119:657, 1981
26. Kietzmann T, Roth U, Freimann S, Jungermann K: Arterial oxygen partial pressures reduce the insulin-dependent induction of the perivenously located gLucokinase in rat hepatocyte cultures: Mimicry of arterial oxygen pressures by H2O2. Biochem J 321:17, 1997
27. Bruzdzinski CJ, Riordan JM, Nordby EC, Suter SM, Gelehrter TD: Isolation and characterization of the rat plasminogen activator inhibitor-1 gene. J Biol Chem 265:2078, 1990
28. Immenschuh S, Hinke V, Ohlmann A, Gifhorn-Katz S, Katz N, Jungermann K, Kietzmann T: Transcriptional activation of the heme oxygenase-1 gene by cGMP via a cAMP response element/activator protein-1 element in primary cultures of rat hepatocytes. Biochem J 334:141, 1998
29. Zeheb R, Rafferty UM, Rodriguez MA, Andreasen P, Gelehrter TD: Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1. Thromb Haemost 58:1017, 1987
30. Dignam JD, Lebovitz RM, Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475, 1983
31. Semenza GL, Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447, 1992
32. Kvietikova I, Wenger RH, Marti HH, Gassmann M: The hypoxia-inducible factor-1 DNA recognition site is cAMP-responsive. Kidney Int 51:564, 1997
33. Bunn HF, Poyton RO: Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76:839, 1996
34. Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, Leung S, Roe R, Wiener C, Yu A: Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 51:553, 1997
35. Liu Y, Cox SR, Morita T, Kourembanas S: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 77:638, 1995
36. Kvietikova I, Wenger RH, Marti HH, Gassmann M: The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res 23:4542, 1995
37. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271:32529, 1996
38. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ: Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 91:6496, 1994
39. Rolfs A, Kvietikova I, Gassmann M, Wenger RH: Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 272:20055, 1997
40. Wenger RH, Rolfs A, Kvietikova I, Spielmann P, Zimmermann DR, Gassmann M: The mouse gene for hypoxia-inducible factor-1alpha - genomic organization, expression and characterization of an alternative first exon and 5′ flanking sequence. Eur J Biochem 246:155, 1997
41. Beck I, Weinmann R, Caro J: Characterization of hypoxia-responsive enhancer in the human erythropoietin gene shows presence of hypoxia-inducible 120-Kd nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells. Blood 82:704, 1993
42. Carmeliet P, Collen D: Gene targeting and gene transfer studies of the plasminogen/plasmin system: Implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J 9:934, 1995
43. Carmeliet P, Collen D: Vascular development and disorders: Molecular analysis and pathogenic insights. Kidney Int 53:1519, 1998
44. Semenza GL: Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med 131:207, 1998
45. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604, 1996
46. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435, 1996
47. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4:923, 1998
48. Risberg B, Stenberg B: Modulation of tissue fibrinolysis from hypoxia and hyperoxia. Thromb Res 38:129, 1985
49. Pinsky DJ, Liao H, Lawson CA, Yan SF, Chen JX, Carmeliet P, Loskutoff DL, Stern DM: Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 102:919, 1998
50. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ: Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89:6998, 1992
51. Lupu F, Bergonrelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK: Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 13:1090, 1993
52. Robbie LA, Booth NA, Brown AJ, Bennett B: Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 16:539, 1996
53. Schnaper HW, Barnathan ES, Mazar A, Maheshwari S, Ellis S, Cortez SL, Baricos WH, Kleinman HK: Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 165:107, 1995
54. Pepper MS, Sappino AP, Montesano R, Orci L, Vassalli JD: Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J Cell Physiol 153:129, 1992
55. Montesano R, Pepper MS, Mohle SU, Risau W, Wagner EF, Orci L: Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62:435, 1990
56. Ryan HE, Lo J, Johnson RS: HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17:3005, 1998
57. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Ewerchin D, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshet E: Role of HIF-1 alpha or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485, 1998
58. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94:8104, 1997
59. Jiang BH, Agani F, Passaniti A, Semenza GL: V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res 57:5328, 1997
60. Liu G, Shuman MA, Cohen RL: Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60:501, 1995
61. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl HJ: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54:4671, 1994
62. Grondahl HJ, Christensen IJ, Rosenquist C, Brunner N, Moundsen HT, Dano K, Blichert TM: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513, 1993
63. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Janicke F, Graeff H: Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55:401, 1994